About
MELAS Treatment
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
290
By Phase
PHASE2: 4PHASE1: 3
By Status
TERMINATED: 3COMPLETED: 2ENROLLING_BY_INVITATION: 1RECRUITING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06961344Lead Sponsor
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
PHASE2Enrolling by invitation
44 participants
Started: Aug 18, 2025 · Completed: Jul 31, 2028
NCT06402123Lead Sponsor
A Phase 2b Study of Zagociguat in Patients With MELAS
PHASE2Recruiting
44 participants
Started: Sep 10, 2024 · Completed: Jun 20, 2026
NCT04798989Lead Sponsor
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
PHASE2Terminated
12 participants
Started: Nov 2, 2021 · Completed: Nov 28, 2022
NCT04972227Lead Sponsor
Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
PHASE1Completed
48 participants
Started: Sep 10, 2021 · Completed: Apr 18, 2022
NCT04475549Lead Sponsor
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
PHASE2Terminated
8 participants
Started: Nov 13, 2020 · Completed: Jan 23, 2022
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...